1. Home
  2. XNCR vs NNNN Comparison

XNCR vs NNNN Comparison

Compare XNCR & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xencor Inc.

XNCR

Xencor Inc.

HOLD

Current Price

$18.36

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo Anbio Biotechnology Class A Ordinary Shares

NNNN

Anbio Biotechnology Class A Ordinary Shares

HOLD

Current Price

$40.63

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XNCR
NNNN
Founded
1997
2021
Country
United States
Germany
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.0B
IPO Year
2013
2025

Fundamental Metrics

Financial Performance
Metric
XNCR
NNNN
Price
$18.36
$40.63
Analyst Decision
Buy
Analyst Count
11
0
Target Price
$23.20
N/A
AVG Volume (30 Days)
758.3K
26.4K
Earning Date
11-05-2025
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.06
Revenue
$150,132,000.00
$8,185,146.00
Revenue This Year
$22.09
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$721.40
Revenue Growth
38.16
21.95
52 Week Low
$6.92
$5.18
52 Week High
$27.24
$55.65

Technical Indicators

Market Signals
Indicator
XNCR
NNNN
Relative Strength Index (RSI) 68.18 72.16
Support Level $15.69 $21.13
Resistance Level $17.83 $29.38
Average True Range (ATR) 1.01 4.59
MACD 0.10 1.85
Stochastic Oscillator 91.72 91.32

Price Performance

Historical Comparison
XNCR
NNNN

About XNCR Xencor Inc.

Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.

Share on Social Networks: